


In the Claims:

What is claimed is:

1. (Previously presented) A compound of Formula I, or a pharmaceutically acceptable salt thereof:



wherein R₁ is isopropenyl or isopropyl;

X is selected from the group of C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₄₋₉ spirocycloalkyl, C₄₋₉ spirocycloalkenyl, C₄₋₈ oxacycloalkyl, C₄₋₈ dioxacycloalkyl, C₆₋₈ oxacycloalkenyl, C₆₋₈ dioxacycloalkenyl, C₆ cyclodialkenyl, C₆ oxacyclodialkenyl, C₆₋₉ oxaspirocycloalkyl and C₆₋₉ oxaspirocycloalkenyl ring,

wherein X is substituted with A, and wherein A is -C₁₋₆ alkyl-halo;

Y is selected from the group of -COOR₂, -C(O)NR₂SO₂R₃, -C(O)NHSO₂NR₂R₂, -NR₂SO₂R₂, -SO₂NR₂R₂, -C₃₋₆ cycloalkyl-COOR₂, -C₂₋₆ alkenyl-COOR₂, -C₂₋₆ alkynyl-COOR₂, -C₁₋₆ alkyl-COOR₂, -alkylsubstituted C₁₋₆ alkyl, -CF₂-COOR₂, -NHC(O)(CH₂)_n-COOR₂, -SO₂NR₂C(O)R₂, -tetrazole, and -CONHOH, wherein n = 1-6;


R₂ is-H, -C₁₋₆ alkyl, -alkylsubstituted C₁₋₆ alkyl or -arylsubstituted C₁₋₆ alkyl;

W is absent, or is -CH₂ or -CO;

R₃ is-H, -C₁₋₆ alkyl or -alkylsubstituted C₁₋₆ alkyl;

BMS12295T

R₄ is selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ alkyl-C₃₋₆ cycloalkyl, -C₁₋₆ substituted -C₁₋₆ alkyl, -C₁₋₆ alkyl-Q₁, -C₁₋₆ alkyl-C₃₋₆ cycloalkyl-Q₁, aryl, heteroaryl, substituted heteroaryl, -COR₆, -SO₂R₇, -SO₂NR₂R₂, and



wherein G is selected from the group of -O-, -SO₂- and -NR₁₂;


wherein Q₁ is selected from the group of -C₁₋₆ alkyl, -C₁₋₆ fluoroalkyl, heteroaryl, substituted heteroaryl, halogen, -CF₃, -OR₂, -COOR₂, -NR₈R₉, -CONR₈R₉ and -SO₂R₇;

R₅ is selected from the group of -H, -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -C₁₋₆ alkylsubstituted alkyl, -C₁₋₆ alkyl-NR₈R₉, -COR₃, -SO₂R₇ and -SO₂NR₂R₂;

with the proviso that R₄ or R₅ cannot be -COR₆ when W is -CO;

with the further proviso that only one of R₄ or R₅ can be selected from the group of --COR₆, -SO₂R₇ and -SO₂NR₂R₂;

or when W is absent or is -CH₂, then R₄ and R₅ can be taken together with the adjacent N to form




R₆ is selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ alkyl-substitutedalkyl, -C₃₋₆ cycloalkyl, -C₃₋₆ substitutedcycloalkyl-Q₂, -C₁₋₆ alkyl-Q₂, -C₁₋₆ alkyl-substitutedalkyl-Q₂, -C₃₋₆ cycloalkyl-Q₂, aryl-Q₂, -NR₁₃R₁₄, and -OR₁₅;

wherein Q₂ is selected from the group of aryl, heteroaryl, substituted heteroaryl, -OR₂, -COOR₂, -NR₈R₉, SO₂R₇, -CONHSO₂R₃, and -CONHSO₂NR₂R₂;

R₇ is selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl, -C₃₋₆ cycloalkyl, -CF₃, aryl, and heteroaryl;

R_8 and R_9 are independently selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, -C₁₋₆ alkyl-Q₂, and -COOR₃, or R_8 and R_9 are taken together with the adjacent N to form a cycle selected from the group of:



M is selected from the group of -R₁₅, -SO₂R₂, -SO₂NR₂R₂, -OH and -NR₂R₁₂;

V is selected from the group of -CR₁₀R₁₁, -SO₂-, -O- and -NR₁₂-;


with the proviso that only one of R_8 or R_9 can be -COOR₃;

R_{10} and R_{11} are independently selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl and -C₃₋₆ cycloalkyl;

BMS12295T

R₁₂ is selected from the group of -H, -C₁₋₆ alkyl, -alkylsubstituted C₁₋₆ alkyl, -CONR₂R₂, -SO₂R₃, -SO₂NR₂R₂;

R₁₃ and R₁₄ are independently selected from the group of -H, -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -C₁₋₆ substituted alkyl, -C₁₋₆ alkyl-Q₃, -C₁₋₆ alkyl-C₃₋₆ cycloalkyl-Q₃, C₁₋₆ substituted alkyl-Q₃ and



Q₃ is selected from the group of heteroaryl, substituted heteroaryl, -NR₂R₁₂, -CONR₂R₂, -COOR₂, -OR₂, and -SO₂R₃;


R₁₅ is selected from the group of -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -C₁₋₆ substituted alkyl, -C₁₋₆ alkyl-Q₃, -C₁₋₆ alkyl-C₃₋₆ cycloalkyl-Q₃ and -C₁₋₆ substituted alkyl-Q₃;

R₁₆ is selected from the group of -H, -C₁₋₆ alkyl, -NR₂R₂, and -COOR₂;
with the proviso that when V is -NR₁₂-; R₁₆ cannot be -NR₂R₂; and

R₁₇ is selected from the group of -H, -C₁₋₆ alkyl, -COOR₃, and aryl.

2. (Original) The compound as claimed in claim 1, wherein R₁ is isopropenyl.
3. (Original) The compound as claimed in claim 2, wherein W is absent.
4. (Original) The compound as claimed in claim 1, wherein X is C₄₋₈ cycloalkenyl.
5. (Original) The compound as claimed in claim 4, wherein X is C₆ cycloalkenyl.


6. (Original) The compound as claimed in claim 5, wherein A is C₁-C₃ alkyl-halo.
7. (Original) The compound as claimed in claim 6, wherein A is methyl-fluoro.
8. (Original) The compound as claimed in claim 1, wherein A is methyl-halo.
9. (Original) The compound as claimed in claim 8, wherein A is methyl-fluoro.
10. (Original) The compound as claimed in claim 1, wherein Y is -COOR₂.
11. (Original) The compound as claimed in claim 10, wherein Y is -COOH.
12. (Previously presented) A compound, or a pharmaceutically acceptable salt thereof, which is selected from the group of:



13. (Original) A pharmaceutical composition which comprises one or more of the compounds as claimed in claim 1, together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.

14. (Original) A pharmaceutical composition which comprises one or more of the compounds as claimed in claim 12, together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.

15. (Original) A pharmaceutical composition which comprises the compound



together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.


Claim 16 is cancelled.

17. (Withdrawn) A method for treating a mammal infected with the HIV virus comprising administering to said mammal an antiviral effective amount of a compound as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents.

Claims 18-20 are cancelled.

21. (Original) The compound as claimed in claim 9, wherein Y is -COOH.

22. (Previously presented) A compound of Formula I, including pharmaceutically acceptable salts-or a pharmaceutically acceptable salt thereof:



wherein R_1 is isopropenyl or isopropyl;

X is selected from the group of C_{4-8} cycloalkyl, C_{4-8} cycloalkenyl, C_{4-9} spirocycloalkyl, C_{4-9} spirocycloalkenyl, C_{4-8} oxacycloalkyl, C_{4-8} dioxacycloalkyl, C_{6-8} oxacycloalkenyl, C_{6-8} dioxacycloalkenyl, C_6 cyclodialkenyl, C_6 oxacyclodialkenyl, C_{6-9} oxaspirocycloalkyl and C_{6-9} oxaspirocycloalkenyl ring,

wherein X is substituted with A, wherein A is $-C_{1-6}$ alkyl-halo;


Y is selected from the group of $-COOR_2$, $-C(O)NR_2SO_2R_3$, $-C(O)NHSO_2NR_2R_2$, $-NR_2SO_2R_2$, $-SO_2NR_2R_2$, $-C_{3-6}$ cycloalkyl- $COOR_2$, $-C_{2-6}$ alkenyl- $COOR_2$, $-C_{2-6}$ alkynyl- $COOR_2$, $-C_{1-6}$ alkyl- $COOR_2$, $-alkylsubstituted\ C_{1-6}\ alkyl$, $-COOR_2$, CF_2-COOR_2 , $-NHC(O)(CH_2)_n-COOR_2$, $-SO_2NR_2C(O)R_2$, $-tetrazole$, and $-CONHOH$,
wherein $n=1-6$;

R_2 is $-H$, $-C_{1-6}$ alkyl, $-alkylsubstituted\ C_{1-6}\ alkyl$ or $-arylsubstituted\ C_{1-6}\ alkyl$;

W is absent, CH_2 or CO ;

R_3 is $-C_{1-6}$ alkyl or $-alkylsubstituted\ C_{1-6}\ alkyl$;

R_4 is selected from the group of $-H$, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $C(OR_3)_2-C_{3-6}$ cycloalkyl, $-C_{1-6}$ substituted alkyl, $-C_{1-6}$ alkyl- C_{3-6} cycloalkyl, $-C_{1-6}$ alkyl- Q_1 , $-C_{1-6}$ alkyl- C_{3-6} cycloalkyl- Q_1 , aryl, heteroaryl, substituted heteroaryl, $-COR_6$, $-COCOR_6$, $-SO_2R_7$, $-SO_2NR_2R_2$,



with the proviso that R₄ or R₅ cannot be COR₆ or COCOR₆ when W is CO;

wherein Q₁ is selected from the group of heteroaryl, substituted heteroaryl, halogen, -CF₃, -OR₂, -COOR₂, -NR₈R₉, -CONR₁₀R₁₁ and -SO₂R₇;

R₅ is selected from the group of -H, -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -C₁₋₆ alkylsubstituted alkyl, -C₁₋₆ alkyl-NR₈R₉, -COR₁₀, -COR₆, -COCOR₆, -SO₂R₇ and -SO₂NR₂R₂;

with the proviso that only one of R₄ or R₅ can be selected from the group of -COR₆, -COCOR₆, -SO₂R₇ and -SO₂NR₂R₂;

or when W is absent or is CH₂, then R₄ and R₅ can be taken together with the adjacent N to form




R₆ is selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ alkyl-substitutedalkyl, -C₃₋₆ cycloalkyl, -C₃₋₆ substitutedcycloalkyl-Q₂, -C₁₋₆ alkyl-Q₂, -C₁₋₆ alkyl-substitutedalkyl-Q₂, -C₃₋₆ cycloalkyl-Q₂, aryl-Q₂, -NR₁₃R₁₄, and -OR₁₅;

wherein Q₂ is selected from the group of aryl, heteroaryl, substituted heteroaryl, -OR₂, -COOR₂, -NR₈R₉, SO₂R₇, -CONHSO₂R₃, and -CONHSO₂NR₂R₂;


BMS12295T

R₇ is selected from the group of -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl, -C₃₋₆ cycloalkyl, -CF₃, aryl, and heteroaryl;

R₈ and R₉ are independently selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, -C₁₋₆ alkyl-Q₂, and -COOR₃, and R₈ and R₉ can also be independently selected from the group of



or R₈ and R₉ are taken together with the adjacent N to form a cycle selected from the group of:



with the proviso that only one of R₈ or R₉ can be -COOR₃;

R₁₀ and R₁₁ are independently selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl and -C₃₋₆ cycloalkyl,


or R₁₀ and R₁₁ are taken together with the adjacent N to form



BMS12295T

R₁₂ is selected from the group of -C₁₋₆ alkyl, -C₁₋₆ alkyl-OR; -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl, -C₃₋₆ cycloalkyl, -COR₇, -COONR₂₂R₂₃, -S(O)_mR₇, and -SONR₂₄R₂₅, wherein m = 1 or 2;

R₁₃ and R₁₄ are independently selected from the group of -H, -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -C₁₋₆ substituted alkyl, -C₁₋₆ alkyl-Q₃, -C₁₋₆ alkyl-C₃₋₆ cycloalkyl-Q₃, C₁₋₆ substituted alkyl-Q₃ and



Q₃ is selected from the group of heteroaryl, substituted heteroaryl, -NR₂₀R₂₁, -CONR₂R₂, -COOR₂, -OR₂, and -SO₂R₃;


R₁₅ is selected from the group of -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -C₁₋₆ substituted alkyl, -C₁₋₆ alkyl-Q₃, -C₁₋₆ alkyl-C₃₋₆ cycloalkyl-Q₃ and -C₁₋₆ substituted alkyl-Q₃;

R₁₆ is selected from the group of -H, -C₁₋₆ alkyl, -NR₂R₂, and -COOR₃;

R₁₇ is selected from the group of -H, -C₁₋₆ alkyl, -COOR₃, and aryl;

R₂₀ and R₂₁ are independently selected from the group of -H, -C₁₋₆ alkyl, -C₁₋₆ substituted alkyl, -C₁₋₆ substituted alkyl-OR₂, and -COR₃,


or R₂₀ and R₂₁ are taken together with the adjacent N to form a cycle selected from the group of



with the proviso that only one of R_{20} or R_{21} can be $-\text{COR}_3$;

R_{22} and R_{23} are independently selected from the group of H, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{1-6}$ substituted alkyl, and $-\text{C}_{1-6}$ cycloalkyl,

or R_{22} and R_{23} are taken together with the adjacent N to form a cycle selected from the group of



R_{24} and R_{25} are independently from the group of H, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{1-6}$ substituted alkyl, $-\text{C}_{1-6}$ alkyl- Q_5 , $-\text{C}_{1-6}$ cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and

Q_5 is selected from the group of halogen and SO_2R_3